TScan Therapeutics, Inc.
TScan Therapeutics, Inc. (Nasdaq: TCRX) is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer and autoimmune disorders. Its lead candidate, TSC-101, is being studied for patients with acute myeloid leukemia and myelodysplastic syndrome undergoing allogeneic… From the company’s description.
Over the twelve months to Jun 30, 2026, TScan Therapeutics, Inc. reported revenue of $7.11M, up 2.2% from a year earlier, and a net loss of $117.71M. Operations used $116.28M in cash. In fiscal 2025, it reported revenue of $10.32M, up 266.7% from fiscal 2024, and a net loss of $129.77M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What TScan Therapeutics, Inc. does
In the company’s own words
TScan Therapeutics, Inc. (Nasdaq: TCRX) is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer and autoimmune disorders. Its lead candidate, TSC-101, is being studied for patients with acute myeloid leukemia and myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation, with the goal of eliminating residual disease and preventing relapse. The company is developing additional blood-cancer candidates targeting CD45, as well as therapies for solid tumors that combine TCRs selected according to each patient’s tumor targets; its initial solid-tumor targets include HPV16, MAGE-A4 and PRAME. It is also researching potential treatments for ankylosing spondylitis, ulcerative colitis and scleroderma, and collaborates with Amgen on target discovery for Crohn’s disease. TScan operates an internal good manufacturing practices facility and uses a non-viral system to engineer T cells. In 2025, 42 patients had enrolled in its Phase 1 ALLOHA trial and undergone transplantation.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1783328
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns TScan Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · TScan Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do TScan Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of TScan Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in TScan Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”